Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by B. Kolatch
570 Safety and Efficacy of Bertilimumab, a Human Anti-Eotaxin-1 Monoclonal Antibody, in Bullous Pemphigoid in a Phase 2a Study
Journal of Investigative Dermatology
Biochemistry
Dermatology
Cell Biology
Molecular Biology
040 Th/Tc9 and Th/Tc17 Pathways Are Augmented in Moderate-To-Extensive Bullous Pemphigoid Patients and Suppressed by Bertilimumab
Journal of Investigative Dermatology
Biochemistry
Dermatology
Cell Biology
Molecular Biology
Related publications
Orphan Designation: Bertilimumab, Treatment of Bullous Pemphigoid
Case Medical Research
Safety and Efficacy of Ofatumumab, a Fully Human Monoclonal Anti-Cd20 Antibody, in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia: A Phase 1-2 Study
Blood
Biochemistry
Immunology
Cell Biology
Hematology
Anti-Pd-1 Monoclonal Antibody MEDI0680 in a Phase I Study of Patients With Advanced Solid Malignancies
Journal for ImmunoTherapy of Cancer
Oncology
Molecular Medicine
Pharmacology
Cancer Research
Allergy
Immunology
A Phase 1 Study of Anti-TGFβ Receptor Type-Ii Monoclonal Antibody LY3022859 in Patients With Advanced Solid Tumors
Cancer Chemotherapy and Pharmacology
Cancer Research
Toxicology
Oncology
Pharmacology
Safety Profile and Clinical Activity of Multiple Subcutaneous Doses of MEDI-528, a Humanized Anti-Interleukin-9 Monoclonal Antibody, in Two Randomized Phase 2a Studies in Subjects With Asthma
BMC Pulmonary Medicine
Pulmonary
Respiratory Medicine
A Phase I First-In-Human Study of Nesvacumab (REGN910), a Fully Human Anti-Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients With Advanced Solid Tumors
Clinical Cancer Research
Cancer Research
Oncology
Phase 1 Experience With an Anti-Glycotope Monoclonal Antibody, RAV12, in Recurrent Adenocarcinoma
Clinical Cancer Research
Cancer Research
Oncology
Bullous Pemphigoid
A Phase I Study of Farletuzumab, a Humanized Anti-Folate Receptor Α Monoclonal Antibody, in Patients With Solid Tumors
Investigational New Drugs
Oncology
Pharmacology
